Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials in Maplewood, Minnesota

3 studies are recruiting for metastatic head and neck squamous cell carcinoma in Maplewood, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (a…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Saint John's Hospital - Healtheast, Maplewood, Minnesota
    Locations
    229 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT05136196 on ClinicalTrials.gov

  2. Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

    This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary s…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Saint John's Hospital - Healtheast, Maplewood, Minnesota
    Locations
    199 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06589804 on ClinicalTrials.gov

  3. FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

    Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, r…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Site #0156, Maplewood, Minnesota
    Locations
    203 in total
    Run by
    Bicara Therapeutics

    See if you can join NCT06788990 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.